Metabolism

New Preliminary Findings on Potential Response Indicator of Rakuten Medical's Alluminox Treatment from Phase 2 Window of Opportunity Study at SNMMI 2023

Retrieved on: 
Friday, June 30, 2023
CT, PIT, Society, PMID, SNMMI, Fluorescence, Molecular imaging, Society of Nuclear Medicine and Molecular Imaging, Clinical trial, Shimadzu, Cancer, PET, Head, Cell, Cytoplasm, Development, National Cancer Institute, Cooperative research and development agreement, Metabolism, Patient, Data analysis, Acquisition, Charles François Duhoux, SAN, Annual general meeting, HNSCC, Squamous-cell carcinoma, NCI, EPUB, NIH, Neck, Safety, 18F-FDG, Pharmaceutical industry, Medical imaging

SAN DIEGO, June 30, 2023 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform, today announced that new interim evaluation data from the ASP-1929-103 study has been presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting held from June 24 to 27.  ASP-1929-103 is a Phase 2, open-label, single-arm, window of opportunity study* of Alluminox treatment (photoimmunotherapy: PIT) using an antibody-dye conjugate ASP-1929 with fluorescence imaging (ClinicalTrials.gov Identifier: NCT05182866) in patients with operable primary or recurrent head and neck squamous cell carcinoma (HNSCC) or cutaneous squamous cell carcinoma (cuSCC).  

Key Points: 
  • ASP-1929-103 is the very first clinical trial of Alluminox treatment in operable cancer.
  • As part of this trial, early time point (1 day) 18F-FDG PET/CT imaging was investigated as a potential response indicator of Alluminox treatment.
  • The preliminary, descriptive imaging analysis based on interim evaluation of 6 patients in ASP-1929-103 study presented during the meeting showed that 18F-FDG PET/CT imaging demonstrates a therapeutic response 1 day after Alluminox treatment using ASP-1929.
  • ASP-1929-103 is a Phase 2, open-label, single-arm, window of opportunity study* of Alluminox treatment (PIT) using an anti-EGFR antibody-dye conjugate, ASP-1929 with fluorescence imaging in patients with operable primary or recurrent HNSCC or cuSCC.

Healthcare Data Breach: Stueve Siegel Hanson LLP Investigates Potential Claims Against Enzo Biochem

Retrieved on: 
Wednesday, June 28, 2023
Biotechnology, COVID-19, Cancer, Metabolism, Infection, Multimedia, History, Capital One, Data breach, Name, Patient, Social Security, Social, T-Mobile, Pharmaceutical industry, Privacy, Equifax

KANSAS CITY, Mo., June 28, 2023 /PRNewswire/ -- Stueve Siegel Hanson LLP , a national leader in data breach and privacy cases, is investigating potential claims against Enzo Biochem and its subsidiary, Enzo Clinical Labs, resulting from a data breach that exposed millions of individuals' sensitive personal information.

Key Points: 
  • KANSAS CITY, Mo., June 28, 2023 /PRNewswire/ -- Stueve Siegel Hanson LLP , a national leader in data breach and privacy cases, is investigating potential claims against Enzo Biochem and its subsidiary, Enzo Clinical Labs, resulting from a data breach that exposed millions of individuals' sensitive personal information.
  • Stueve Siegel Hanson, a national leader in data breach and privacy cases, is investigating the Enzo Biochem data breach.
  • What is Enzo Biochem: Enzo Biochem is a sciences and biotechnology company that holds itself out as "a pioneer in molecular diagnostics, leading the convergence of clinical laboratories."
  • Stueve Siegel Hanson attorneys have represented data breach victims in many of the largest data breach cases in history, including cases against Equifax, T-Mobile, and Capital One.

Earth Company Launches With a Line of Accessible and Nutrient-Rich Plant-Based Meals, Created With Celebrity Chef & Co-Founder Matthew Kenney

Retrieved on: 
Wednesday, June 28, 2023
Retail, Health, Environment, Sustainability, Fitness & Nutrition, General Health, Food, Beverage, Taste, Human, Mineral, Nutrient, Immunity, Meal, Red Earth (company), Nutritional science, Vitamin, Metabolism, Lunch, Carbohydrate, Longevity, Conditional sentence, Fast food, Dietary supplement, Convenience food

Today, Earth Company launches to bring its mission of making nutritionally complete and plant-based meals accessible to consumers, while tackling industry challenges of scale and cost.

Key Points: 
  • Today, Earth Company launches to bring its mission of making nutritionally complete and plant-based meals accessible to consumers, while tackling industry challenges of scale and cost.
  • Founded by entrepreneur Max Koenig and celebrity chef Matthew Kenney, Earth Company will enter the market with a line of warm bowls, including curry, chili and bolognese options, shipped to consumers ready to eat.
  • “After understanding the benefits of a plant-based diet, we both made the switch to a new routine and saw immediate benefits.
  • Being able to make this experience accessible with Earth Company was the natural next step,” said Co-Founder & Celebrity Chef Matthew Kenney.

Appia Bio Expands Leadership Team With Sylvaine Cases, Ph.D. Appointed Chief Business Officer and Alex Babayan, Ph.D. as Vice President, Head of Regulatory Affairs

Retrieved on: 
Wednesday, June 28, 2023
Amgen, Private sector, ACUA, University, University of California, Irvine academics, Cancer research, Cancer, Axicabtagene ciloleucel, Janssen, Head, University of California, Allotransplantation, Research, Stem cell, TCR, Institut Gustave Roussy, Health, Arete, CAR, Metabolism, Patient, Investment, CBO, Biology, LOS, Gladstone Institutes, Therapy, Kite, BLA, IND, Tumor microenvironment, Bangladesh Technical Education Board, Pharmacology, Pharmaceutical industry, Sanofi

LOS ANGELES, June 28, 2023 /PRNewswire/ -- Appia Bio, Inc., a biotechnology company developing allogeneic chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-NKT) cell therapies from hematopoietic stem cells (HSCs) for patients with cancer, today announced the appointments of Sylvaine Cases, Ph.D. as chief business officer (CBO) and Alex Babayan, Ph.D. as vice president, head of regulatory affairs.

Key Points: 
  • "We are delighted to have Sylvaine and Alex join the Appia Bio team.
  • Sylvaine is a thoughtful business executive with deep understanding of our industry from both sides of the table.
  • Alex brings long-term considered insight based on his broad global regulatory affairs experience in cell therapy.
  • Dr. Babayan joins Appia Bio from Instil Bio where he was vice president and head of regulatory affairs.

ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting

Retrieved on: 
Wednesday, June 28, 2023
Insulin, Diet, Weight loss, Pancreas, OGTT, Diabetes, T2DM, Organization, Metabolism, Alloxan, Blood, Annual general meeting, Liver, ASMBS, Research, Pig, Society, NIH, Bariatric surgery, AU, Pharmaceutical industry, AUC, Zucker

“Type 2 Diabetes Mellitus (T2DM) remains challenging to effectively treat, despite medication, surgery and diet,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences.

Key Points: 
  • “Type 2 Diabetes Mellitus (T2DM) remains challenging to effectively treat, despite medication, surgery and diet,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences.
  • “ReShape’s DBSN™ device selectively modulates vagal block and stimulation to the liver and pancreas to manage blood glucose.
  • Increased glycemic control has been demonstrated in a Zucker rat model of T2DM as well as in an alloxan treated swine model of T2DM.
  • There was an apparent, but non-significant, increase in baseline insulin following stimulation and block experiments (pre-experiments =10.7±2.6 µIU/mL, post-experiments=15.4±2.9 µIU/mL, p=0.28).

Allurion Presents New Data at the 2023 ASMBS Annual Meeting Demonstrating Mean Weight Reduction of Over 20%

Retrieved on: 
Wednesday, June 28, 2023
Research, Medical Devices, Surgery, Diabetes, Fitness & Nutrition, Other Health, Managed Care, General Health, Health, Science, Overweight, Metabolism, Patient, ASMBS, Obesity, BMI, Multimedia, Society, American Society for Metabolic & Bariatric Surgery, Holyoke Medical Center

Allurion , a company dedicated to ending obesity, today announced results from a 232-patient study investigating the Allurion Program.

Key Points: 
  • Allurion , a company dedicated to ending obesity, today announced results from a 232-patient study investigating the Allurion Program.
  • Patients with severe obesity (BMI ≥ 40) lost on average 20.5% of their total body weight and those in the BMI
  • The results were presented during the 2023 American Society for Metabolic & Bariatric Surgery (ASMBS) Annual Meeting in Las Vegas.
  • “We believe this study underscores the potential versatility of the Allurion Program across a wide spectrum of BMI,” he stated.

AMRA Medical´s Latest Research Finds a Strong Association Between Personalized Body Fat Z-Scores Describing Skewed Fat Distribution and Specific Cardiometabolic Risk Profiles

Retrieved on: 
Wednesday, June 28, 2023
Radiology, Pharmaceutical, Research, Oncology, Medical Devices, Hospitals, Fitness & Nutrition, Science, Clinical Trials, Managed Care, Medical Supplies, Cardiology, General Health, FDA, Biotechnology, Diabetes, Health, Health Technology, Abstract, Biobank, Obesity, Cardiovascular disease, Type 2 diabetes, Multimedia, CVD, Metabolism, Magnetic resonance spectroscopic imaging, Magnetic resonance imaging, Risk, American Society for Metabolic & Bariatric Surgery, Liver, ASMBS, BMI, T2D, Society, Bariatric surgery, Medical imaging, Soft drink

AMRA researchers together with Linköping University used personalized imaging-derived obesity phenotypes, based on a large, population-based study, to investigate cardiometabolic risk stratification in individuals with obesity.

Key Points: 
  • AMRA researchers together with Linköping University used personalized imaging-derived obesity phenotypes, based on a large, population-based study, to investigate cardiometabolic risk stratification in individuals with obesity.
  • The study used ‘body fat z-scores’, describing how much each individual with obesity is deviating from the amount of visceral fat that is commonly observed with their sex and BMI.
  • Results showed that excess accumulation of visceral fat (a high visceral fat z-score) at any given BMI was significantly associated with increased risk of CVD and T2D.
  • Conversely, excess amounts of subcutaneous- and liver- fat was associated with a lower risk of cardiovascular disease indicating a potentially protective fat distribution pattern.

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

Retrieved on: 
Wednesday, June 28, 2023
Professional Services, Other Health, Health, Environmental Issues, Philanthropy, Environmental Health, Pharmaceutical, Environmental, Social and Governance (ESG), Other Philanthropy, Environment, Sustainability, Carbon, Atlantic Forest, ARCOS, Life, Farmer, Survival, Forest, Fungus, Palace, CBA, Patient, Greening Australia, National Fish Habitat Partnership, Paris, European Forest Institute, Mammal, National Fish and Wildlife Foundation, Biodiversity loss, Regeneration, Immunology, Instituto de Pesquisas e Estudos Sociais, Versailles, Yvelines, Multimedia, IPE, Climate change, Water, Bird, EFI, Partnership, Nature, Metabolism, Greenhouse gas, Tree, Biopharmaceutical, AstraZeneca, Butterfly, Biodiversity, Rare, Forestry England, Forestry, Agriculture, Recycling, Sene West (Ghana parliament constituency)

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “The twin crises of climate change and biodiversity loss are damaging the planet and harming human health.

Key Points: 
  • Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “The twin crises of climate change and biodiversity loss are damaging the planet and harming human health.
  • Through AZ Forest, we are working with local communities and ecological experts to deliver reforestation at scale, as well as support biodiversity and sustain livelihoods.
  • Forests and trees are the backbone for life on our planet and the basis for human health and wellbeing.
  • AZ Forest projects support planetary and human health with significant socio-economic co-benefits and are part of AstraZeneca’s science-based net zero strategy, Ambition Zero Carbon .

City of Hope diabetes experts present new research on beta cells, insulin secretion and islet transplantation at annual American Diabetes Association (ADA) Conference

Retrieved on: 
Tuesday, June 27, 2023
Ruth B., Insulin resistance, City of Hope, Failure, Life, Drug discovery, Mitochondrion, Survival, Glucagon, Science, Metabolism, Patient, American Diabetes Association, ADA, AKT1, Conditional sentence, City of Hope National Medical Center, Endocrine & Metabolism Research Institute, Ageing, Epigenetics, Research, Overnutrition, Liver, DNA, Insulin, Cancer, Cell, Transplant, LOS, Therapy, Translation, Molecule, Arthur, Glucose, Clinical trial, Nutrient, Quality of life, Genomics, Inflammation, Proteomics, Metabolomics, Endocrinology, Gene, Medical device, Pharmaceutical industry, Phosphorus, Antibiotics, Dietary supplement, Dentistry, Hope, City, Diabetes

City of Hope diabetes scientists presented research at American Diabetes Association conference.

Key Points: 
  • City of Hope diabetes scientists presented research at American Diabetes Association conference.
  • Sangeeta Dhawan, Ph.D. , an associate professor in City of Hope's Department of Translational Research & Cellular Therapeutics , discussed epigenetic control of beta cell stress response and senescence.
  • Recent research by Dhawan and members of her lab outlined novel findings identifying the mechanisms by which cellular stress causes senescence.
  • Islet transplantation involves isolating insulin producing cells from a donated pancreas and infusing them into a patient with diabetes.

Intermittent fasting and calorie counting about equal for weight loss – new study

Retrieved on: 
Tuesday, June 27, 2023
Insulin, Obesity, University, Diet, Body composition, Method, Glucose, Weight loss, Eating, Nutrient, Research, University of Illinois Chicago School of Law, Annals of Internal Medicine, Chicago, Waist, Metabolism, Functional analytic psychotherapy, Internal medicine, Time, Ageing, Fasting, Human, Foodservice, Dietary supplement, Fast food

The traditional approach to weight loss is to count calories and try to reduce the number consumed each day.

Key Points: 
  • The traditional approach to weight loss is to count calories and try to reduce the number consumed each day.
  • Intermittent fasting – and the popular version known as time-restricted eating – could be a simpler option for people wanting to achieve a healthy weight.
  • But is intermittent fasting any better than calorie counting for losing weight?
  • The diets were then adjusted to help maintain this weight loss over the next six months.
  • The researchers hypothesised that participants focusing on reducing the number of hours they ate would achieve and maintain weight loss better than participants focusing on counting calories.
  • These findings support previous studies that have found similar weight loss when comparing time-restricted eating and other popular versions of intermittent fasting (such as the 5:2 diet), to daily calorie restriction.
  • The new study shows that time-restricted eating can lead to weight loss without explicit instruction to reduce calorie intake.

Substantial counselling

    • However, one important aspect of this study that makes it difficult to conclude that these interventions alone are enough to help people lose weight is the fact that participants in both dietary intervention groups received a lot of counselling during the study.
    • Interestingly, a recent study found that time-restricted eating without additional support did not lead to weight loss after three months.
    • There were also substantial differences in weight loss between individual participants on each diet.